Real-world comparison of Ixazomib, lenalidomide and dexamethasone vs lenalidomide and dexamethasone in relapsed and refractory multiple myeloma

Warning

This publication doesn't include Faculty of Arts. It includes Faculty of Medicine. Official publication website can be found on muni.cz.
Authors

MINARIK J. PIKA T. RADOCHA J. JUNGOVA A. STRAUB J. JELINEK T. POUR Luděk PAVLICEK P. MISTRIK M. BROŽOVÁ Lucie KRHOVSKA P. MACHALKOVA K. JINDRA P. SPICKA I. PLONKOVA H. ŠTORK Martin BACOVSKY J. CAPKOVA L. SYKORA M. KESSLER P. STEJSKAL L. HEINDORFER A. ULLRYCHOVA J. MAISNAR V. HAJEK R.

Year of publication 2019
Type Conference abstract
MU Faculty or unit

Faculty of Medicine

Citation
Description We have performed a face to face comparison of all-oral triplet ixazomib, lenalidomide and dexamethasone (IRD) versus lenalidomide and dexamethasone (RD) in patients with relapsed and refractory multiple myeloma (RRMM) in the routine clinical practice. The primary endpoint was progression free survival (PFS), secondary end points included response rates and overall survival (OS).
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.